Neuphoria Therapeutics (NEUP)
Develops BNC210 for anxiety and trauma-related disorders through virtualized clinical development.
Something off on this page? Send us feedback.
Develops BNC210, an oral neuropsychiatry candidate for social anxiety disorder and PTSD, through a virtualized clinical-development model; without approved products or product sales, future economics depend on development, regulatory, financing, and partnering outcomes.
Develops BNC210, an oral small molecule for social anxiety disorder and post-traumatic stress disorder. The candidate modulates the alpha-7 nicotinic acetylcholine receptor; its social-anxiety program has been advanced for acute, as-needed treatment around anxiety-provoking events, while the PTSD program has supported later-stage planning. A single research-and-development segment, rather than commercial pharmaceutical divisions, contains the core proprietary program; no approved-product portfolio or product-sales business existed in the latest filing.
Combines an American listed parent and FDA-oriented clinical strategy with Australian corporate and scientific roots. Executes virtualized drug development by sponsoring trials and controlling intellectual property while relying on contract research organizations, clinical sites, laboratories, and contract manufacturers. BNC210 therefore concentrates clinical, regulatory, intellectual-property, formulation, manufacturing, and vendor-execution dependencies across nearly the entire proprietary pipeline.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| May 15, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | |
| Dec 5, 2025 | H.C. Wainwright | Target | $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $19.4M · Total debt $34.2K · Total assets $34.8M · Shareholders' equity $29.4M
- Revenue
- $0
- Operating income
- −$1.2M
- Net income
- −$505.1K
No dividends on record.
| Institutions19 holders · as of Mar 31, 2026 | 32.53% | 1.76M shares | |
| Otherremainder | 67.47% | 3.65M shares |
5.40M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Lynx1 Capital Management LPInstitution | 16.20% | 875,328 | 13Fas of Mar 31, 2026 |
Advisorshares Investments LLCInstitution | 2.87% | 155,367 | 13Fas of Mar 31, 2026 |
Shay Capital LLCInstitution | 2.79% | 151,010 | 13Fas of Mar 31, 2026 |
Balyasny Asset Management L.P.Institution | 2.63% | 142,183 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.82% | 98,516 | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 21, 2025 | Lynx1 Capital Management LP | 10 percent owner | +639,110 | $5.14 |
- VistaGen Therapeutics
Intranasal fasedienol and BNC210 target acute social anxiety.
- Vanda Pharmaceuticals
VQW-765 and BNC210 pursue on-demand social-anxiety treatment.
- Tonix Pharmaceuticals
Early intranasal oxytocin research overlaps in social anxiety.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neuphoria Therapeutics | $3.75 | −1.06% | $20.3M | — | — | — | — |
| VistaGen Therapeutics | $0.2500 | +0.64% | $10.9M | — | — | 4.4 | +504.9% |
| Vanda Pharmaceuticals | $5.60 | +1.36% | $332.5M | — | — | 1.5 | −3.9% |
| Tonix Pharmaceuticals | $13.50 | +0.90% | $213.3M | — | — | 7.3 | +577.9% |
| Median | — | — | 4.4 | +504.9% |